Trials / Unknown
UnknownNCT00643825
Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients
Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or "Stop and Go" in Glioblastoma Patients: The PATSGO Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay relapses in patients with glioblastoma compared to the standard care consisting in observation with brain MRI every 3 months and rechallenging with TMZ at relapse (Stop and Go arm).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temozolomide | Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD |
| DRUG | Temozolomide | Observation till Progression then rechallenging with TMZ |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-01-01
- Completion
- 2012-01-01
- First posted
- 2008-03-26
- Last updated
- 2010-07-23
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00643825. Inclusion in this directory is not an endorsement.